Get started
Author

Alev Akyol

Observed name: AKYOL, ALEV
OpenAlex ID: A5026737754
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study
2023 · Stephen M. Ansell, Paul J. Bröckelmann, et al. · Blood Advances · 96
PDF
Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy
2023 · Jonathan W. Friedberg, Rodolfo Bordoni, et al. · Blood · 43
Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up
2023 · Pier Luigi Zinzani, Armando Santoro, et al. · Blood Advances · 40
PDF
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults
2025 · Stephen Daw, Peter D. Cole, et al. · JAMA Oncology · 21
Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744.
2023 · Paul David Harker-Murray, Peter D. Cole, et al. · Journal of Clinical Oncology · 11
PDF
Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma
2023 · Armando Santoro, Alison J Moskowitz, et al. · Blood · 11
PDF
Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma
2024 · Pier Luigi Zinzani, Gilles Salles, et al. · Blood Advances · 8
PDF
Longer Follow-up of Golcadomide (GOLCA), a Cereblon E3 Ligase Modulator (CELMoD™) Agent ± Rituximab (RTX), in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
2024 · Jean-Marie Michot, Franck Morschhauser, et al. · Blood · 4
PDF
An Uncommon Presentation of Chronic Lymphocytic Leukemia: Bilateral Hearing Loss
2007 · Alev Akyol, Ahmet Öztürk, et al. · 4
The combination of body mass index and serum creatinine levels predicts survival in patients with Hodgkin lymphoma treated with nivolumab in the CheckMate 205 study
2025 · Rosaria De Filippi, Fortunato Morabito, et al. · OncoImmunology · 2
Current practice of autologous hematopoietic progenitor cell mobilization in adult patients with multiple myeloma and lymphoma: The results of a survey from Turkish hematology research and education group (ThREG)
2017 · Emre Tekgündüz, Fatih Demirkan, et al. · Transfusion and Apheresis Science · 2
Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma
2025 · Nathalie A. Johnson, Pier Luigi Zinzani, et al. · Future Oncology · 1
PDF
ABCL-1115: Golcadomide, a Cereblon E3 Ligase Modulator (CELMoD) Agent, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Phase 1/2 Results
2025 · Emmanuel Bachy, Jean-Marie Michot, et al. · Clinical Lymphoma Myeloma & Leukemia · 1
Trial in Progress: Phase 1/2 Study of Cereblon-Modulating Agent Golcadomide (BMS-986369/CC-99282) in Relapsed or Refractory (R/R) T-Cell Lymphomas (TCLs) (GOLSEEK-3)
2024 · Koji Izutsu, Noriko Fukuhara, et al. · Blood · 1
PDF
Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD, plus rituximab (R) versus investigator’s choice (IC) in patients (pts) with relapsed/refractory follicular lymphoma (R/R FL) who have received ≥ 1 line of systemic therapy: GOLSEEK-4, a phase (Ph) 3, randomized study.
2026 · Clémentine Sarkozy, Eliza Anne Hawkes, et al. · Journal of Clinical Oncology
Golseek-4: A Phase 3, randomized study of golcadomide, a potential, first-in-class, oral CELMoD™ agent, plus rituximab versus Investigator's choice in patients with Relapsed/Refractory follicular lymphoma who have received ≥1 line of systemic therapy
2025 · Eliza Hawkes, Clementine Sarkozy, et al. · Blood
IBCL-1121: GOLSEEK-4: A Multicenter Phase 3 Randomized Open-Label Study Comparing Efficacy and Safety of Golcadomide + Rituximab Vs Investigator's Choice in Patients With Relapsed/Refractory Follicular Lymphoma
2025 · Alex Herrera, Eliza Hawkes, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: IBCL-1121 GOLSEEK-4: A Multicenter Phase 3 Randomized Open-Label Study Comparing Efficacy and Safety of Golcadomide + Rituximab Vs Investigator’s Choice in Patients With Relapsed/Refractory Follicular Lymphoma
2025 · Alex Herrera, Eliza Hawkes, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-1115 Golcadomide, a Cereblon E3 Ligase Modulator (CELMoD) Agent, With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Updated Phase 1/2 Results
2025 · Emmanuel Bachy, Jean-Marie Michot, et al. · Clinical Lymphoma Myeloma & Leukemia
Abstract 5222: Biomarkers associated with complete metabolic response (CMR) to nivolumab and brentuximab vedotin (nivo + BV) for the treatment of children, adolescents, and young adults (CAYA) with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) in the CheckMate 744 study
2022 · Charlie Garnett-Benson, Ron Ammar, et al. · Cancer Research
İmmün Trombositopeninin Gebeliğin Seyri Üzerine Etkisi Retrospektif Çok Merkezli Türkiye Verileri
2016 · MADEN, MUHAMMET, ERMİŞ TURAK, ESRA, et al. · AYBU AVESIS
Platelet Count and Platelet Distribution Width Increase in Lung Cancer Patients Akci̇ğer Kanseri̇ Hastalarinda Platelet Sayisi Ve Platelet Dağilim Araliği Artmiştir
2009 · Bülent Karagöz, Hakan Demirci, et al.
Works count: 22
Citation count: 245
H-index: 7
I10-index: 6
Year
Topic
Type